Melinta secures $142M BARDA deal to target pediatric and 'biothreat' indications for antibiotics
10 Jul 2023
Acquisition
Melinta Therapeutics secured a BARDA deal worth nearly $142 million to make two currently approved antibiotics available for children.
The deal comes roughly three years after Deerfield Management acquired the antibiotics company and tapped CEO Christine Ann Miller to restructure it. Despite the rising threat of antimicrobial resistance (AMR), Big Pharma has largely retreated from the high-risk field where many antibiotics fail in development while others languish due to a lack of available funding. The ones that do get approved are used sparingly to preserve efficacy and slow further resistance.
Preview
Source: EndPoints
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.